Option chain shows key data for Range Capital Acquisition's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Range Capital Acquisition.

Range Capital Acquisition (NASDAQ:RANG) Stock, Option Chain

Range Capital Acquisition Corp is a blank check company.

Range Capital Acquisition Corp. - Ordinary Shares

Range Capital Acquisition Corp

Range Capital Acquisition Corp. - Rights

Range Cancer Therapeutics ETF

Range Impact Inc

Range India Financials ETF

Range Resources Corp

Ranger Energy Services, Inc. Class A Common Stock

Ranger Energy Services Inc

Ranger Equity Bear Bear ETF

Ranger Gold Corp

Rangers Protocol

Mizuho analyst Ben Chaiken maintains Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) with a Outperform and raises the price target from $117 to $120.

News

Price Target

Analyst Ratings

Mizuho Maintains Outperform on Marriott Vacations, Raises Price Target to $120

GTBP

GT Biopharma  Files Request For Withdrawal With SEC  With Respect To Withdrawal Of Form S-1 Registration Statement, Filed On Dec. 23

Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 700 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $148.546 million which beat the analyst consensus estimate of $146.380 million by 1.48 percent. This is a 15.92 percent increase over sales of $128.145 million the same period last year.

Earnings

Earnings Beats

XMTR

Xometry Q4 2024 Adj. EPS $0.06 Beats $0.03 Estimate, Sales $148.546M Beat $146.380M Estimate

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy and maintains $15 price target.

Reiteration

TBPH

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $15 Price Target

Citigroup analyst Asiya Merchant maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and raises the price target from $60.45 to $64.

Citigroup Maintains Buy on Western Digital, Raises Price Target to $64

Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.32) by 3.13 percent. This is a 22.5 percent increase over losses of $(0.40) per share from the same period last year.

FULC

Fulcrum Therapeutics Q4 GAAP EPS $(0.31) Beats $(0.32) Estimate

DOCN

DigitalOcean Holdings Q4 2024 Adj. EPS $0.49 Beats $0.34 Estimate, Sales $204.925M Beat $200.507M Estimate

Stantec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STN#NYSE">STN</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.69 by 14.49 percent. This is a 31.67 percent increase over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $1.06 billion which beat the analyst consensus estimate of $1.01 billion by 4.65 percent. This is a 15.81 percent increase over sales of $912.70 million the same period last year.

Stantec Q4 Adj $0.79 Beats $0.69 Estimate, Sales $1.06B Beat $1.01B Estimate

Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.15 by 6.67 percent. This is a 75 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $1.02 billion which beat the analyst consensus estimate of $1.01 billion by 0.98 percent. This is a 1.45 percent decrease over sales of $1.03 billion the same period last year.

ELAN

Elanco Animal Health Q4 2024 Adj EPS $0.14 Misses $0.15 Estimate, Sales $1.02B Beat $1.01B Estimate

WIIM

RDHL

RedHill shares are trading higher after the company announced an exclusive licensing agreement with Hyloris Pharmaceuticals for RHB-102, including an upfront payment and up to $60 million in potential milestones.

<ul>
<li>Food Processing to be a Fast-Growing and Nimble Standalone Business with Best-in-Class Technologies for Industrial Protein, Bakery, and Snack Processors</li>
<li>Middleby RemainCo Well-Positioned to Drive Sustainable Growth and Margin Expansion Through Innovation Leadership and Differentiated Go-To-Market Capabilities in Commercial Foodservice and Residential Kitchens</li>
<li>Separation of Food Processing Expected to be Achieved Through Tax-Free Spin-Off and be Completed Early 2026</li>
<li>Company Separately Announces Q4 and Full-Year 2024 Financial Results and Appointment of Independent Directors to its Board</li>
</ul>

MIDD

Middleby To Spin Off Food Processing Unit, Forming Independent Food Processing And Kitchen Equipment Leaders

RedHill Enters Exclusive Development And Commercialization Licensing Agreement With Hyloris Pharmaceuticals For RHB-102; Hyloris Will Pay Co. Upfront Payment And Up To $60M In Potential Milestones

For the full year 2025, the Company expects GAAP revenue of approximately $1.0 billion, representing revenue growth of approximately 5% year-over-year. The Company expects Adjusted Gross Profit Margin to be in the range of 47.0% to 47.5%. The Company expects Adjusted EBITDA to be in the range of $225 million to $235 million and Adjusted Diluted EPS to be in the range of $3.35 to $3.55. The Company's guidance assumes no significant changes in foreign exchange rates.
For the first quarter of 2025, the Company expects GAAP revenue of approximately $232 million to $236 million. The Company expects Adjusted Gross Profit Margin to be in the range of 46.0% to 46.5%. The Company expects Adjusted EBITDA to be in the range of $48 million to $51 million and Adjusted Diluted EPS to be in the range of $0.63 to $0.71. The Company's guidance assumes no significant changes in foreign exchange rates.

Guidance

NOVT

Novanta Expects Q1 Revenue Of $232M-$236M Vs $244.89M Est, Adj EPS Of $0.63-$0.71 Vs $0.78 Est

AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.27 by 25.93 percent. The company reported quarterly sales of $856.65 million which beat the analyst consensus estimate of $829.19 million by 3.31 percent. This is a 0.18 percent decrease over sales of $858.23 million the same period last year.

AHCO

AdaptHealth Q4 2024 GAAP EPS $0.34 Beats $0.27 Estimate, Sales $856.65M Beat $829.19M Estimate

Delek US Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DK#NYSE">DK</a>) reported quarterly losses of $(2.54) per share which beat the analyst consensus estimate of $(2.81) by 9.61 percent. This is a 73.97 percent decrease over losses of $(1.46) per share from the same period last year. The company reported quarterly sales of $2.37 billion which missed the analyst consensus estimate of $2.58 billion by 7.84 percent. This is a 41.38 percent decrease over sales of $4.05 billion the same period last year.

Earnings Misses

Delek US Hldgs Q4 2024 Adj EPS $(2.54) Beats $(2.81) Estimate, Sales $2.37B Miss $2.58B Estimate

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) sees FY2025 sales of $818.000 million-$826.000 million vs $847.01 million analyst estimate.

OFIX

Orthofix Medical Sees FY2025 Sales $818.000M-$826.000M vs $847.01M Est

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.05) by 140 percent. This is a 103.39 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $215.66 million which beat the analyst consensus estimate of $212.71 million by 1.38 percent. This is a 7.61 percent increase over sales of $200.41 million the same period last year.

Orthofix Medical Q4 Adj $0.02 Beats $(0.05) Estimate, Sales $215.66M Beat $212.71M Estimate

Sealed Air Sees FY25 Revenue Of $5.100B - $5.500B Vs. $5.4B Est; Adj EPS Of $2.90 - $3.30 Vs. $3.12 Est.

2025 Financial Guidance: We expect revenue growth to be in the range of 15% to 17%. In addition, we anticipate gross margin to be in the range of 73% - 75%. This includes one-time costs, mainly related to the anticipated BLA approval, impacting gross margin by approximately 1%. Additionally, we expect to be net cash flow positive for the full year.

Biotech

Health Care

General

AXGN

Axogen Expects 2025 Revenue Growth Of 15%-17%, The Company Expects Gross Margin Of 73%-75%

Guidance for Fiscal Year 2025
The Company is providing its financial guidance for fiscal year 2025, as follows:
<ul>
<li>Net revenue of $3.22 billion to $3.36 billion;</li>
<li>Adjusted EBITDA of $670 million to $710 million;</li>
<li>Free cash flow of $180 million to $220 million</li>
</ul>

Comments

Range Capital Acquisition

Range Capital Acquisition (RANG) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga